- Home
- TWFG vs FHTX Comparison
TWFG vs FHTX Comparison
Compare TWFG & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWFG
- FHTX
- Stock Information
- Founded
- TWFG 2001
- FHTX 2015
- Country
- TWFG United States
- FHTX United States
- Employees
- TWFG N/A
- FHTX N/A
- Industry
- TWFG
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- TWFG
- FHTX Health Care
- Exchange
- TWFG NYSE
- FHTX Nasdaq
- Market Cap
- TWFG 377.4M
- FHTX 416.6M
- IPO Year
- TWFG 2024
- FHTX 2020
- Fundamental
- Price
- TWFG $27.31
- FHTX $9.86
- Analyst Decision
- TWFG Buy
- FHTX Strong Buy
- Analyst Count
- TWFG 8
- FHTX 5
- Target Price
- TWFG $27.86
- FHTX $15.40
- AVG Volume (30 Days)
- TWFG 133.8K
- FHTX 191.7K
- Earning Date
- TWFG 08-27-2024
- FHTX 10-31-2024
- Dividend Yield
- TWFG N/A
- FHTX N/A
- EPS Growth
- TWFG N/A
- FHTX N/A
- EPS
- TWFG 40.85
- FHTX N/A
- Revenue
- TWFG $187,281,000.00
- FHTX $35,185,000.00
- Revenue This Year
- TWFG N/A
- FHTX N/A
- Revenue Next Year
- TWFG N/A
- FHTX $18.49
- P/E Ratio
- TWFG $0.67
- FHTX N/A
- Revenue Growth
- TWFG 12.35
- FHTX 61.95
- 52 Week Low
- TWFG $21.31
- FHTX $2.70
- 52 Week High
- TWFG $31.91
- FHTX $10.18
- Technical
- Relative Strength Index (RSI)
- TWFG N/A
- FHTX 64.75
- Support Level
- TWFG N/A
- FHTX $8.54
- Resistance Level
- TWFG N/A
- FHTX $9.75
- Average True Range (ATR)
- TWFG 0.00
- FHTX 0.85
- MACD
- TWFG 0.00
- FHTX 0.10
- Stochastic Oscillator
- TWFG 0.00
- FHTX 88.89
About TWFG TWFG INC
TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.